At the conclusion of this live activity, participants should be better able to:
- Design a comprehensive treatment plan for acne patients based on clinical guidelines, incorporating pharmacologic and nonpharmacologic strategies.
- Discuss the clinical relevance of the most recent research on the etiologies and therapy of acne vulgaris.
- Discuss the topical treatment pipeline for acne.
- Identify patients at risk for various skin lesions, including actinic and seborrheic keratoses and nonmelanoma skin cancers.
- Describe therapeutic approaches to actinic keratosis that optimize efficacy in treating lesions while reducing risk for neoplastic complications
- Differentiate seborrheic keratosis from other skin lesions, particularly melanoma
- Match patients with the most appropriate interventions for effective and cosmetically acceptable treatment of SK lesions.
- Design evidence-based, guideline-driven treatment strategies for patients with AD based on disease severity with the goal of clear or almost clear skin.
- Incorporate strategies for use of new therapies aimed at blocking the inflammatory mediators of AD.
- Identify which allergens are likely to be problematic for patients with atopy and integrate patch testing when appropriate
- Discuss the risks and benefits of CAR-T cell therapy in melanoma.
- Differentiate among potential causes of contact dermatitis and the treatment approaches required.
- Explain the multiple entities that are encompassed by the umbrella term “toxic erythema of chemotherapy” (TEC).
- Discuss the prevention and management of cutaneous AEs associated with chemotherapies and radiation therapy.
- Discuss basic approaches to perform a nail unit biopsy.
- Discuss surgical approaches to treating rhinophyma.
- Incorporate simple surgical tips for large wounds, wound under tension, or to increase efficiency and patient satisfaction.
- Apply basic dermoscopy to the assessment of skin lesions.
- Incorporate newer dermoscopy imaging technologies in clinical practice.
- Describe evidence-based strategies for the diagnosis and pharmacologic management of hyperhidrosis.
- Describe the data on the new topical anticholinergic agents in the management of hyperhidrosis.
- Distinguish key characteristics of emerging and newly approved agents for treating skin infections such as ABSSTI (acute bacterial skin and soft tissue infections).
- Distinguish malignant from nonmalignant suspicious neoplasms.
- Design a management plan for melanomas at all stages of development.
- Design treatment strategies appropriate for pediatric patients with common dermatologic conditions
- Identify characteristics in pediatric patients that suggest increased risk for conversion of benign moles to dysplastic nevi or melanoma
- Describe characteristics of IHs that are more likely to require medical intervention.
- Identify how to diagnose and treat common pediatric hair diseases.
- Differentiate the various photodermatoses from other dermatologic conditions whose symptoms manifest in similar ways.
- Describe the algorithm for the diagnosis of photodermatoses.
- Discuss photoprotection with patients, including pediatric patients and their caregivers.
- Describe the pathophysiology of psoriasis and its associated comorbidities.
- Diagnose and treat patients with psoriasis appropriately, based on current clinical guidelines.
- Design treatment strategies that incorporate biologic therapies into the management of appropriately selected patients with psoriasis.
- Increase routine screening for psoriatic arthritis in patients with psoriasis.
- Design self-education and patient education programs as part of the treatment plan for rosacea treatment.
- Discuss appropriate treatment strategies for rosacea, based on individual signs and symptoms as well as knowledge of the indications, efficacy, and risks of available and emerging rosacea therapies.
- Describe the presentation, diagnosis and management of common tropical diseases.
ACCREDITATION AND DESIGNATION STATEMENTS
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Global Academy for Medical Education, LLC. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.
The University of Louisville School of Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The self-assessment program offered at 19th Annual Caribbean Dermatology Symposium is approved by the American Board of Dermatology (ABD) for MOC-D self-assessment points. Please be sure to report completion of any self-assessment programs on your MOC-D table located in your ABD profile (www.abderm.org).
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 20.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.